US20110237788A1 - Helicobacter pylori bacterium proliferation inhibitor - Google Patents

Helicobacter pylori bacterium proliferation inhibitor Download PDF

Info

Publication number
US20110237788A1
US20110237788A1 US13/063,876 US200913063876A US2011237788A1 US 20110237788 A1 US20110237788 A1 US 20110237788A1 US 200913063876 A US200913063876 A US 200913063876A US 2011237788 A1 US2011237788 A1 US 2011237788A1
Authority
US
United States
Prior art keywords
group
pylori bacteria
beta
proliferation
glcnac1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/063,876
Other languages
English (en)
Inventor
Jun Nakayama
Takashi Shirai
Takashi Yamanoi
Masaya Fujita
Masako Mori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noguchi Institute
Original Assignee
Noguchi Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noguchi Institute filed Critical Noguchi Institute
Assigned to NOGUCHI INSTITUTE, THE reassignment NOGUCHI INSTITUTE, THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MORI, MASAKO, FUJITA, MASAYA, NAKAYAMA, JUN, SHIRAI, TAKASHI, YAMANOI, TAKASHI
Publication of US20110237788A1 publication Critical patent/US20110237788A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A23L33/145—Extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a proliferation inhibitor of Helicobacter pylori bacteria comprising an N-acetylglucosaminyl beta-linked monosaccharide derivative, which can inhibit the proliferation of Helicobacter pylori bacteria as a causative microorganism for diseases such as peptic ulcers, gastric cancers and so on.
  • H. pylori Helicobacter pylori ( H. pylori ) bacteria is a bacteria responsible for peptic ulcers and chronic gastritis (Marshall B. J. et al., Lancet, Vol. I, p. 1311-1315 (1984) and Peek R. M. Jr. et al., Nature Reviews Cancer, Vol. 2, p. 28-37 (2002)). It has been said that the persons infected with H. pylori bacteria would reach almost a half of the world population.
  • H. pylori bacteria inhabits in the superficial mucus secreted from the surface layer of the gastric mucous, but never inhabits in the mucous and the glandular mucus secreted from the mucous deep layer.
  • This glandular mucus inherently contains a sugar chain derived from GlcNAc alpha 1-4Gal beta-group-containing O-glycan having a N-acetyl-glucosamine alpha residue (alpha GlcNAc reside) and a galactose residue (Gal residue).
  • alpha GlcNAc reside
  • Gal residue galactose residue
  • the inventors of the present invention found out that a sugar chain of glycoproteins which are each linked with a core binary-branched O-glycan having an alpha GlcNAc residue at the non-reduced terminal can substantially inhibit the proliferation of H. pylori bacteria and also that this inhibition of the proliferation is achieved by an enzyme activity inhibition of cholesterol alpha glucosyl transferase (CHL alpha GcT) (Hirai Y. et al., Journal of Bacteriology, Vol. 177, p. 5327-5333 (1995)) which exists only in Helicobacters embracing H. pylori bacteria (Kawakubo M. et al., Science, Vol. 305, p. 1003-1006 (2004)).
  • CHL alpha GcT cholesterol alpha glucosyl transferase
  • H. pylori bacteria essentially requires the glucosyl cholesterol components (CGL) for the proliferation, but it cannot synthesize the CGL by itself. Accordingly, it is said that H. pylori bacteria takes in cholesterols from the external world and adds glucose to the region in the proximity to the membrane of the bacterial cell to thus construct the cell wall. In this respect, it would thus be estimated that the foregoing sugar chain of glycoproteins which are each linked with O-glycan carrying the alpha GlcNAc residue has an ability to inhibit the construction of such cell wall, and thus it is expected to be applied to a specific proliferation inhibitor of H. pylori bacteria. However, such complicated sugar chain of glycoproteins having high-molecular weight has to be prepared through multiple troublesome steps under a reaction condition which cannot be fully controlled resulting to require extensive manufacturing facilities and great expense. Therefore, it is not practicable.
  • Japanese Patent Provisional Publication (Translation of PCT Application) No. 2003-517015 discloses Helicobacter pylori bacteria-binding substances as oligosaccharides comprising Gal beta 1,3 GlcNAc structure.
  • Helicobacter pylori bacteria-binding substances are polysaccharides and have quite complicated structure resulting to require multiple steps for preparation which do not permit the mass production of the same.
  • the presently used methods for treating patients infected with H. pylori bacteria are not ones which make use of these sugar chains, but they mainly comprise the step of eradicating bacterial cells through the simultaneous use of the following three kinds of drugs: a kind of proton pump-inhibitor and two kinds of antibiotics.
  • this treatment may induce the generation of resistant bacteria to thus cause the recurrence of the infectious disease and that they may cause side effects.
  • N-acetylglucosaminyl alpha-linked monosaccharide derivative has a significant effect on inhibiting the proliferation of H. pylori bacteria and already filed a patent application (WO2008/084561).
  • the present invention has been developed to solve the foregoing problems. It is an object of the present invention to provide a proliferation inhibitor of H. pylori bacteria comprising a compound that can specifically inhibit the proliferation of H. pylori bacteria, which does not generate resistant bacterium, can be eaten, drunken or taken for a long period of time, can be simply mass-manufactured and can be used for beverages, foods or medical preparations.
  • an N-acetylglucosaminyl beta-linked monosaccharide derivative has more significant effect on inhibiting the proliferation of H. pylori bacteria compared to an N-acetylglucosaminyl alpha-linked monosaccharide derivative, and accomplished the present invention.
  • a proliferation inhibitor of H. pylori bacteria of the present invention developed to accomplish the foregoing objects comprises an N-acetylglucosaminyl beta-linked monosaccharide derivative represented by the following chemical formula (1):
  • Y is an alkyl group, an alkoxyl group, an alkenyl group, an alkynyl group, an aralkyl group, an aryl group, a heteroaryl group, a carboxyl group or an alkoxycarbonyl group.
  • GlcNAc represents the N-acetyl-glucosaminyl group.
  • a diet of the food or the beverage of the present invention comprises the foregoing proliferation inhibitor of H. pylori bacteria.
  • the pharmaceutical preparation of the present invention comprises the foregoing proliferation inhibitor of H. pylori bacteria.
  • the monosaccharide derivative reduces an activity of the cholesterol alpha glucosyl transferase (CHL alpha GcT) to alpha glucosyl to inhibit the proliferation of H. pylori bacteria, and thus it exerts on an anti-bacterial effect towards H. pylori bacteria.
  • CHL alpha GcT cholesterol alpha glucosyl transferase
  • the monosaccharide derivative is a glucose derivative having low molecular weight instead of having a complicated chemical structure, so the derivative can be simply produced and is suitable for the industrial production in commercial quantity.
  • the monosaccharide derivative inhibits the construction of the cell wall of H. pylori bacteria to thus inhibit the proliferation of H. pylori bacteria and therefore, it can show a significant pharmaceutical benefit against H. pylori bacteria.
  • the proliferation inhibitor of H. pylori bacteria may comprise the N-acetylglucosaminyl beta-linked monosaccharide derivative alone and/or other drugs such as antibiotics to thus completely remove H. pylori bacteria from the stomach and to prevent the recurrence of gastric diseases such as chronic gastritis, peptic ulcers, gastric cancers and/or gastric malignant lymphoma.
  • the N-acetylglucosaminyl beta-linked monosaccharide derivative inherently exists in living organisms and specifically inhibits the proliferation of H. pylori bacteria. Therefore, the proliferation inhibitor comprising thereof would have high safety to the human individual. Furthermore, it has been confirmed that the N-acetylglucosaminyl beta-linked monosaccharide derivative, especially ethyl beta-N-acetyl-glucosaminide (GlcNAc1-beta-O-Et) is included in yeast extract widely used for food additives. And the yeast extract is considered to be safe foodstuff in view of the food experiences. Therefore, the proliferation inhibitor comprising this derivative can be repeatedly used for a product to be eaten, drunken or administrated for a long period of time.
  • the N-acetylglucosaminyl beta-linked monosaccharide derivative especially ethyl beta-N-acetyl-glucosaminide (GlcNAc1-bet
  • the diet of the food or the beverage each containing the proliferation inhibitor of H. pylori bacteria of the present invention is useful for alleviating the symptoms of gastric diseases, remedying and/or preventing such diseases.
  • This N-acetylglucosaminyl beta-linked monosaccharide derivative shows a strong pharmaceutical effect of inhibiting the proliferation of H. pylori bacteria. Consequently, when the proliferation inhibitor of H. pylori bacteria is simply incorporated into the diet of these foods and beverages in a small quantity, the resulting diet of the foods and the beverages can show excellent H. pylori bacteria-resistant effects.
  • the pharmaceutical preparation comprising the proliferation inhibitor of H. pylori bacteria of the present invention is effective for curing, alleviating and/or preventing the gastric diseases caused by the H. pylori bacteria such as chronic gastritis and gastric ulcers.
  • the N-acetylglucosaminyl beta-linked monosaccharide derivative shows a strong effect of inhibiting the proliferation of H. pylori bacteria and therefore, an excellent H. pylori bacteria-resistant effect can be developed simply by administrating a small amount of this pharmaceutical preparation and accordingly, the pharmaceutical preparation is useful for the medical therapy of curing gastric diseases without any side-effects.
  • FIG. 1 is a graph showing the H. pylori bacteria-resistant effect of a proliferation inhibitor of H. pylori bacteria comprising an N-acetylglucosaminyl beta-linked monosaccharide derivative (GlcNAc1-beta-O-Et) to which the present invention is applied.
  • GlcNAc1-beta-O-Et N-acetylglucosaminyl beta-linked monosaccharide derivative
  • FIG. 2 is a graph showing the H. pylori bacteria-resistant effect of N-acetyl-glucosamine (GlcNAc1) to which the present invention is not applied.
  • FIG. 3 is a graph showing the H. pylori bacteria-resistant effect of ethanol to which the present invention is not applied.
  • FIG. 4 is a graph showing the body weight change of meriones unguiculatus during the passage of day with or without the administration of the proliferation inhibitor of H. pylori bacteria comprising an N-acetylglucosaminyl beta-linked monosaccharide derivative (GlcNAc1-beta-O-Et) to which the present invention is applied.
  • GlcNAc1-beta-O-Et N-acetylglucosaminyl beta-linked monosaccharide derivative
  • FIG. 5 is a graph showing the count of cultured colonies of H. pylori bacteria isolated from exenterated stomach of meriones unguiculatus with or without the administration of the proliferation inhibitor of H. pylori bacteria comprising an N-acetylglucosaminyl beta-linked monosaccharide derivative (GlcNAc1-beta-O-Et) to which the present invention is applied.
  • GlcNAc1-beta-O-Et N-acetylglucosaminyl beta-linked monosaccharide derivative
  • FIG. 6 is a graph showing the H. pylori bacteria-resistant effect of an N-acetylglucosaminyl alpha-linked monosaccharide derivative (GlcNAc1-alpha-O-Et) to which the present invention is not applied.
  • FIG. 7 is a graph showing the body weight change of meriones unguiculatus during the passage of day with or without the administration of the N-acetylglucosaminyl alpha-linked monosaccharide derivative (GlcNAc1-alpha-O-Et) to which the present invention is not applied.
  • FIG. 8 is a graph showing the count of cultured colonies of H. pylori bacteria isolated from exenterated stomach of meriones unguiculatus with or without the administration of the an N-acetylglucosaminyl alpha-linked monosaccharide derivative (GlcNAc1-alpha-O-Et) to which the present invention is not applied.
  • GlcNAc1-alpha-O-Et N-acetylglucosaminyl alpha-linked monosaccharide derivative
  • the proliferation inhibitor of H. pylori bacteria of the present invention comprises an N-acetylglucosaminyl beta-linked monosaccharide derivative, and it is an effective ingredient for a foodstuff additive or an pharmaceutical preparation.
  • the N-acetylglucosaminyl beta-linked monosaccharide derivative is represented by the foregoing chemical formula (1), or GlcNAc1-beta-O—Y, wherein Y is an alkyl group, an alkoxyl group, an alkenyl group or an alkynyl group each having 1 to 27 carbon atoms; an aralkyl group such as benzyl; an aryl group such as phenyl; a heteroaryl group; a carboxyl group; an alkoxycarbonyl group; cholesterol group and so on. More specifically, the derivative has such a structure that the N-acetyl-glucosaminyl group (GlcNAc) is linked by a beta-glycosi
  • the proliferation inhibitor of H. pylori bacteria is a compound having ethyl group (i.e. GlcNAc1-beta-O-Et) which is included in yeast extract as foodstuff additive. (Iwahara S. et al., Bioscience, Biotechnology, and Biochemistry, Vol. 57, No. 10, p. 1779-1780 (1993)).
  • the N-acetylglucosaminyl beta-linked monosaccharide derivative for example GlcNAc1-beta-O-Et, has a significant effect of inhibition of proliferation on H. pylori bacteria when used even alone.
  • the monosaccharide derivative can control the proliferation ability of H. pylori bacteria to a level of not more than 50%.
  • such culture medium containing the monosaccharide derivative in a concentration of not less than 20 mM thereof can control the proliferation ability of H. pylori bacteria to a level of not more than 5%.
  • This monosaccharide derivative is stable in the culture medium and is not decomposed inside the stomach for several hours.
  • This N-acetylglucosaminyl beta-linked monosaccharide derivative is not only monosaccharide but also a compound simply prepared through a single-step synthetic method and accordingly it can be produced in commercial quantity or scale.
  • this monosaccharide derivative is quite stable since it is a derivative having an aliphatic hydrocarbon substituent group linked to N-acetylglucosaminyl, and the substituent group through the ether bond is hard to be leaved.
  • the aliphatic hydrocarbon group such as an alkyl group is a quite stable residue.
  • This monosaccharide derivative is completely free of any residue harmful to the human individual. Therefore, the safety thereof is considerably high and the monosaccharide derivative can thus be incorporated into the diet of the foods and the beverages as well as pharmaceutical preparations.
  • N-acetylglucosaminyl beta-linked monosaccharide derivative are used as the proliferation inhibitor of H. pylori bacteria.
  • These saccharide derivatives may be used alone, a plurality of them may be used in combination or they may likewise be used in combination with a kind of proton pump-inhibitor such as Lansoprazole or Omeprazole and two kinds of antibiotics such as Amoxicillin and Clarithromycin.
  • This proliferation inhibitor of H. pylori bacteria comprising the N-acetylglucosaminyl beta-linked monosaccharide derivative may likewise be used as an additive for the diet of the foods and the beverages.
  • examples of such diet of the foods and the beverages may be foods, for instance, dairy products such as yoghurt; and beverages such as drink water, cocoa and juices.
  • the diet of these foods and beverages are those continuously ingested. This is because the H. pylori bacteria-proliferation inhibitory effect may further be improved and the continuous ingestion thereof would thus inhibit the peptic diseases, for instance, gastric diseases such as chronic gastritis.
  • This proliferation inhibitor of H. pylori bacteria is used as an effective component to be incorporated into a pharmaceutical preparation.
  • a pharmaceutical preparation may be in any form such as a tablet, a capsule, a granule, a pill, an emulsion, a powder, syrup, a liquid preparation, or an injection.
  • Such a pharmaceutical preparation may further comprise components for preparing each pharmaceutical preparation such as excipients, distilled water and physiological saline; and/or other medical components. It is more preferred that these pharmaceutical preparations should be taken once or continuously to thus improve the H. pylori bacteria-proliferation inhibitory effect and accordingly, the ingestion thereof would permit the curing or alleviation of the peptic diseases, for instance, gastric diseases such as chronic gastritis.
  • Ethoxy 2-acetamide-2-deoxy-N-acetyl-beta-D-glucosaminide (GlcNAc1-beta-O-Et (2)) as an example of the N-acetylglucosaminyl beta-linked monosaccharide derivative represented by the foregoing chemical formula (1) to which the present invention is applied is detailed in this Example 1.
  • This derivative can be synthesized according to the following chemical reaction scheme (3).
  • a proliferation inhibitor of H. pylori bacteria comprising thus GlcNAc1-beta-O-Et (2) was prepared and then biological effectivities thereof were evaluated as following deliberate determinations.
  • H. pylori bacteria The effect of GlcNAc1-beta-O-Et (2) on H. pylori bacteria was confirmed according to the following procedures.
  • Bacterial cells of H. pylori bacteria ATCC 43504 stored in a brucella broth culture medium frozen at ⁇ 80° C. were cultured in the same culture medium (3 mL) supplemented with 10% horse serum at 35° C. in the presence of 15% CO 2 for 40 hours according to the shaking culture technique, the movement or behavior of bacterial cells was observed under a microscope and non-coccoid type bacterial cells of H. pylori bacteria were recovered.
  • the culture medium was inspected for the optical density (OD) values at 600 nm, followed by the dilution thereof with Muller-Hinton broth culture medium supplemented with 5.5% horse serum such that the number of bacterial cells present therein was equal to 4 ⁇ 10 7 , and 3 mL thereof in total was cultured at 35° C. in the presence of 15% CO 2 for 24 hours according to the shaking culture technique, followed by the confirmation of the movement or behavior of bacterial cells by a microscope to thus give an H. pylori bacteria-containing culture medium (bacterial cell density: 2 ⁇ 10 7 /mL) used in the test for the confirmation of the effect of the foregoing compound. On the other hand, there were prepared Muller-Hinton broth culture mediums without any bacterial cell of H.
  • each of the resulting culture mediums was added to the foregoing H. pylori bacteria-containing culture medium in mixing ratio of 1:1 (by volume) (total volume: 100 ⁇ L each; on a 96-well plate), followed by the mixing there of and the subsequent cultivation at 35° C. in the presence of 15% CO 2 for 96 hours.
  • the bacterial cell density thus proliferated was determined by the measurement of the OD values at 600 nm, followed by the comparison of the result observed for the sample to which the candidate compound was added with that observed for the negative control free of any candidate compound (the control depicted in FIG. 1 ) to thus evaluate the proliferation inhibitory effect of the compound.
  • GlcNAc1-beta-O-Et in a defined constant amount of the H. pylori bacteria-containing culture medium was measured by high performance liquid chromatography.
  • a concentration of GlcNAc1-beta-O-Et therein was determined by conversion using a calibration curve which was beforehand prepared from various definite concentrations of standard GlcNAc1-beta-O-Et and peak areas of high pressure liquid chromatogram thereof. According to the determination, 6% of GlcNAc1-beta-O-Et in the defined constant amount of the H. pylori bacteria-containing culture medium was reduced in comparison with initial concentration thereof. Consequently it was obvious that 6% of GlcNAc1-beta-O-Et in the H. pylori bacteria-containing culture medium was decomposed to GlcNAc and ethanol (EtOH).
  • GlcNAc which can be produced by the decomposition of GlcNAc1-beta-O-Et, does not show any proliferation inhibitory effect, even when the concentration thereof is extremely high as 50 mM.
  • incubation of H. pylori bacteria as same as protocols of Example 2 was performed by using ethanol of 1.25 volume % (214 mM), 2.5 volume % (428 mM) and 5 volume % (856 mM) instead of using GlcNAc1-beta-O-Et in Example 2.
  • concentration of proliferated H. pylori bacteria was determined by measuring under 600 nm, comparing OD of culture including ethanol with OD of culture including no ethanol (the control depicted in FIG. 3 ), and then evaluating the proliferation inhibitory effect of the compound.
  • ethanol which can be produced by the decomposition of GlcNAc1-beta-O-Et, shows proliferation inhibitory effect barely, when the concentration thereof is extremely high as 5 volume %.
  • GlcNAc1-beta-O-Et is a pharmacologically active substance in the proliferation inhibitor of H. pylori bacteria. And it is obvious that the decomposed substances from GlcNAc1-beta-O-Et do not indicate any pharmacologically activity of inhibiting proliferation of H. pylori bacteria.
  • Type strain of H. pylori bacteria (ATCC 43504 strain) was used as strain for infection. After stock strain thereof was recovered in Brain Heart Infusion (BHI) culture medium, which is available from Nissui Pharmaceutical Co., Ltd., including 10% horse serum, which is available from Dainippon Sumitomo Pharma Co., Ltd., and then cultured in the culture medium at 37° C. under microaerophilic condition using a microaerophilic incubator for 3 days. Finally the concentration thereof was adjusted to approximately 5 ⁇ 10 6 colony-forming-unit/mL (CFU/mL).
  • BHI Brain Heart Infusion
  • the meriones unguiculatus were fasted from 24 hours earlier of infection of Helicobacter pylori bacteria to 4 hours later of the infection thereof.
  • the day of infection was defined as day 0.
  • body weight was measured by a weight scale respectively. The results thereof are shown in FIG. 4 .
  • Stomach was respectively isolated from thus 10 animals of each group, and added into a centrifuging tube containing 5 mL of a phosphate buffer solution (PBS) to be homogenized with Polytron Homogenizer. 0.1 mL of the obtained homogenate was spread on Poamedia Vi Helico-S agar medium which is available from Eiken Chemical Co., Ltd. And then the bacterium were cultured at 37° C. under microaerophilic condition as same as above-mentioned incubation for culture. The formed violet colonies were counted.
  • PBS phosphate buffer solution
  • Example 2 Effect on inhibiting the proliferation was investigated as same as Example 2 by using 300 or 1000 mg/kg/day of GlcNAc1-alpha-O-Et instead of 300 mg/kg/day of GlcNAc1-beta-O-Et as administration amount on Example 1 (consultation of Table 1). And determination of body weight, general remarks of symptoms, and count of viable bacteria by using count of colony were also investigated according to above-mentions. They were carried out by above-mentioned statistical procedure. The results of the effect on inhibiting the proliferation are shown in FIG. 6 , the results of variance of the body weight are shown in FIG. 7 , and the results of the determination of count of viable bacteria are shown in FIG. 8 .
  • GlcNAc1-alpha-O-Et did not almost indicate the effect on inhibiting the proliferation of H. pylori bacteria under in vitro in comparison with GlcNAc1-beta-O-Et.
  • the statistical significant difference of the count of viable bacteria between the administration group of 300 mg/kg/day of GlcNAc1-alpha-O-Et in the proliferation inhibitor of H. pylori bacteria and the control group was not observed at all.
  • the statistical significant difference on the administration group of much higher amount as 1000 mg/kg/day of GlcNAc1-alpha-O-Et was eventually observed towards the control group, and the count of H. pylori bacteria on the administration group was reduced by 1 ⁇ 3 in comparison with the control group.
  • the proliferation inhibitor of H. pylori bacteria is useful for the diet of the food or beverage and the pharmaceutical preparation for proliferation inhibitor of H. pylori bacteria.
  • N-acetylglucosaminyl beta-linked monosaccharide derivative linkage shows its antibacterial effect against H. pylori bacteria in such a mechanism that it can inhibit all kinds of proliferative activities essential or indispensable to the growth of the bacterial cells, completely unlike the conventional antibiotics and therefore, it is quite useful as an effective H. pylori bacteria-resistant agent.
  • the proliferation inhibitors of H. pylori bacteria comprising these sugar derivatives are effective components for additives for supplements and the diet of the foods and the beverages.
  • the diet of the foods and the beverages each comprising the proliferation inhibitors of H. pylori bacteria are useful as functional foods and beverages as well as health foods and beverages.
  • the pharmaceutical preparation comprising the proliferation inhibitors of H. pylori bacteria is accordingly useful for curing, alleviation and/or prevention of digestive disease especially gastric disease such as gastritis, gastric ulcer and duodenal ulcer, which are caused by of H. pylori bacteria.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
US13/063,876 2008-10-10 2009-10-09 Helicobacter pylori bacterium proliferation inhibitor Abandoned US20110237788A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-263880 2008-10-10
JP2008263880 2008-10-10
PCT/JP2009/067657 WO2010041746A1 (fr) 2008-10-10 2009-10-09 Inhibiteur de prolifération de bactérie helicobacter pylori

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/067657 A-371-Of-International WO2010041746A1 (fr) 2008-10-10 2009-10-09 Inhibiteur de prolifération de bactérie helicobacter pylori

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/737,609 Continuation US8859511B2 (en) 2008-10-10 2013-01-09 Proliferation inhibitor of Helicobacter pylori bacteria

Publications (1)

Publication Number Publication Date
US20110237788A1 true US20110237788A1 (en) 2011-09-29

Family

ID=42100692

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/063,876 Abandoned US20110237788A1 (en) 2008-10-10 2009-10-09 Helicobacter pylori bacterium proliferation inhibitor
US13/737,609 Expired - Fee Related US8859511B2 (en) 2008-10-10 2013-01-09 Proliferation inhibitor of Helicobacter pylori bacteria

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/737,609 Expired - Fee Related US8859511B2 (en) 2008-10-10 2013-01-09 Proliferation inhibitor of Helicobacter pylori bacteria

Country Status (4)

Country Link
US (2) US20110237788A1 (fr)
EP (1) EP2345656B1 (fr)
JP (1) JP5383692B2 (fr)
WO (1) WO2010041746A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100197616A1 (en) * 2007-01-12 2010-08-05 The Noguchi Institute Proliferation inhibitor of helicobacter pylori including alpha-n-acetyl-glucosaminyl bond-containing monosaccharide derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2710807A (en) * 1952-05-27 1955-06-14 American Home Prod Food products containing glucosides of nu-acetyl-d-glucosamine
US20040086514A1 (en) * 1999-12-15 2004-05-06 Karl-Anders Karlsson Novel helicobacter pylori-binding substances and use thereof
US20090054355A1 (en) * 2007-01-12 2009-02-26 Shinshu University Proliferation Inhibitor Of Helicobacter Pylori Including Alpha-N-Acetyl-Glucosaminyl Bond-Containing Monosaccharide Derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152513A (en) 1977-06-01 1979-05-01 University Of Delaware Preparation of alkyl glycosides of amino sugars
WO1994003184A1 (fr) 1992-07-31 1994-02-17 Neose Pharmaceuticals, Inc. Compositions destinees a traiter et inhiber les ulceres gastriques et duodenaux
AU9258798A (en) 1997-08-08 1999-03-01 Hoechst Marion Roussel Deutschland Gmbh Substituted tetrahydropyrane derivatives, method for producing same, the ir use as medicine or diagnostic agent, as well as medicine containing same
DE60327211D1 (de) * 2002-06-28 2009-05-28 Glykos Finland Oy Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall
US7871793B2 (en) 2004-02-20 2011-01-18 Burnham Institute For Medical Research Antimicrobial carbohydrates and methods of using same
JP5140246B2 (ja) * 2006-03-15 2013-02-06 公益財団法人野口研究所 Ｎ−アセチルグルコサミンの誘導体を含有するピロリ菌増殖抑制剤
WO2008032817A1 (fr) * 2006-09-14 2008-03-20 Riken Chaîne de sucre ayant une activité à l'encontre de l'helicobacter pylori

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2710807A (en) * 1952-05-27 1955-06-14 American Home Prod Food products containing glucosides of nu-acetyl-d-glucosamine
US20040086514A1 (en) * 1999-12-15 2004-05-06 Karl-Anders Karlsson Novel helicobacter pylori-binding substances and use thereof
US20090054355A1 (en) * 2007-01-12 2009-02-26 Shinshu University Proliferation Inhibitor Of Helicobacter Pylori Including Alpha-N-Acetyl-Glucosaminyl Bond-Containing Monosaccharide Derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nagai T. Clinical and experimental studies on ethyl-N-acetyl-D-glucose as bifidus factor. Pediatr Int 3:83-102, November, 1960. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100197616A1 (en) * 2007-01-12 2010-08-05 The Noguchi Institute Proliferation inhibitor of helicobacter pylori including alpha-n-acetyl-glucosaminyl bond-containing monosaccharide derivatives
US8575117B2 (en) 2007-01-12 2013-11-05 The Noguchi Institute Proliferation inhibitor of helicobacter pylori including alpha-n-acetyl-glucosaminyl bond-containing monosaccharide derivatives

Also Published As

Publication number Publication date
US8859511B2 (en) 2014-10-14
EP2345656A4 (fr) 2014-07-09
JPWO2010041746A1 (ja) 2012-03-08
US20130131004A1 (en) 2013-05-23
WO2010041746A1 (fr) 2010-04-15
EP2345656B1 (fr) 2018-05-02
EP2345656A1 (fr) 2011-07-20
JP5383692B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
CN108135925A (zh) 聚糖组合物及其用途
TWI772384B (zh) 嗜粘蛋白阿克曼氏菌增殖材料
EP4293103A1 (fr) Bifidobacterium lactis et son application
JP2007507214A (ja) プレバイオティック効果の分析
CN116209363A (zh) 生成α-葡萄糖苷酶抑制剂的新型凝结芽孢杆菌CC菌株
JP6793380B2 (ja) スクロース摂取による血糖値上昇を抑制する物質の評価方法、スクリーニング方法及び製造方法
US8859511B2 (en) Proliferation inhibitor of Helicobacter pylori bacteria
JP2000217546A (ja) マンノース含有ヘテロオリゴ糖からなる甘味剤、病原菌感染抑制剤、整腸剤又は澱粉の老化抑制剤及び該剤からなる飲食品、医薬品又は飼料。
US8575117B2 (en) Proliferation inhibitor of helicobacter pylori including alpha-n-acetyl-glucosaminyl bond-containing monosaccharide derivatives
US20230285343A1 (en) Composition for inhibiting growth of bacterium having menaquinone synthesis pathway through futalosine or futalosine derivative
EP2027862B1 (fr) Composition pour augmenter la fonction immunitaire comprenant du zinc et un nigerooligosaccharide
KR20170017176A (ko) 장 내 유산균 증가용 조성물 및 이를 이용한 유산균 생산 방법
JPS6220993B2 (fr)
JP6607595B2 (ja) １，４−ジヒドロキシ−２−ナフトエ酸誘導体
JP2019043952A (ja) 腸内環境改善剤およびβ−グルクロニダーゼ活性阻害剤
KR20200040984A (ko) 바실러스 아밀로리퀘파시엔스 rwl-1 균주 배양액에서 분리된 화합물을 유효성분으로 포함하는 위장질환 예방 또는 치료용 약학적 조성물
US20220298111A1 (en) Compositions and methods for treating metabolic disease
EP4309662A1 (fr) Micro-organismes convertir l'inositol en butyrate
KR102085900B1 (ko) 바실러스 아밀로리퀘파시엔스 rwl-1 균주 배양액에서 분리된 화합물을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물
WO2023068279A1 (fr) Procédé de criblage de bactéries du genre blautia
KR20230113195A (ko) 위암 환자 장내균총 분석을 통한 면역 저하 진단과 장내균총을 이용한 테라그노시스 조성물
CN114886104A (zh) 一种具有高α-葡萄糖苷酶抑制活力的天然高倍甜味剂及其应用
CN1627949A (zh) 适合抑制哺乳动物感染的环聚糖

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOGUCHI INSTITUTE, THE, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKAYAMA, JUN;SHIRAI, TAKASHI;YAMANOI, TAKASHI;AND OTHERS;SIGNING DATES FROM 20110602 TO 20110603;REEL/FRAME:026545/0186

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION